Virologic, Immunologic And Clinical Response Of Infants To Antiretroviral Therapy In Kampala, Uganda

Simple item page
dc.contributor.authorTukei, Vincent J.
dc.contributor.authorMurungi, Miriam
dc.contributor.authorAsiimwe, Alice R.
dc.contributor.authorMigisha, Daniella
dc.contributor.authorMaganda, Albert
dc.contributor.authorKitaka, Sabrina Bakeera
dc.contributor.authorKalyesubula, Israel
dc.contributor.authorMusoke, Philippa
dc.contributor.authorKekitiinwa, Adeodata
dc.date.accessioned2022-01-29T11:11:09Z
dc.date.available2022-01-29T11:11:09Z
dc.date.issued2013
dc.description.abstractAntiretroviral therapy (ART) is known to save lives. Among HIV-infected infants living in resource constrained settings, the short and long term benefits of ART are only partially known. This study was designed to determine the virologic, immunologic and clinical outcomes of antiretroviral therapy in a cohort of HIV-infected infants receiving care from an outpatient clinic in Kampala, Uganda.A prospective cohort of HIV-infected infants receiving treatment at the Baylor-Uganda clinic was analyzed. Patients were diagnosed, enrolled and followed up at the clinic. HIV viral load, CD4 cell counts and clinical progress were assessed during follow-up. Descriptive statistical analysis and logistic regression modeling to determine predictors of treatment success were conducted.Of 91 HIV-infected infants enrolled into the cohort, 53 (58.2%) infants were female; 43 (47.3%) were 6 months of age or younger, and 50 (55.6%) had advanced HIV/AIDS disease (Clinical stage 3 or 4). Eighty four infants started ART and 78 (92.9%) completed 6 months of treatments. Fifty six (71.8%) infants attained virologic suppression by month-6 of ART, and at month-12 of ART, the cumulative probability of attaining viral suppression was 83.1%. None of the baseline infant factors (age, sex, WHO stage, CD4 cell percent, weight for age, or height for age z-score) predicted treatment success. There was an increase in CD4 cells from a baseline mean of 23% to 30% at month-6 of treatment (p<0.001) and by month-24 of ART, the mean CD4 percent was 36%. A total of 7 patients died while on ART and another 7 experienced adverse events that were related to treatment.Our results show that, even among very young patients from resource constrained settings, ART dramatically suppresses HIV replication, allows immune recovery and clinical improvement, and is safe. However, baseline characteristics do not predict recovery in this age group.en_US
dc.identifier.citationTukei, V. J., Murungi, M., Asiimwe, A. R., Migisha, D., Maganda, A., Bakeera-Kitaka, S., ... & Kekitiinwa, A. (2013). Virologic, immunologic and clinical response of infants to antiretroviral therapy in Kampala, Uganda. BMC pediatrics, 13(1), 1-9.https://doi.org/10.1186/1471-2431-13-42en_US
dc.identifier.urihttps://nru.uncst.go.ug/xmlui/handle/123456789/1603
dc.language.isoenen_US
dc.publisherBMC pediatricsen_US
dc.subjectInfant; HIV;Antiretroviral therapy; Mortality; Malnutritionen_US
dc.titleVirologic, Immunologic And Clinical Response Of Infants To Antiretroviral Therapy In Kampala, Ugandaen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Virologic, Immunologic And Clinical Response Of.pdf
Size:
230.48 KB
Format:
Adobe Portable Document Format
Description:
Virologic, Immunologic And Clinical Response Of Infants To Antiretroviral Therapy In Kampala, Uganda
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences